Advertisement

New Sexual Adverse Effects Added to Finasteride Labels — Physician’s First Watch

Medical News |
April 13, 2012

New Sexual Adverse Effects Added to Finasteride Labels

The labels of the alopecia drug Propecia (finasteride 1 mg) and the benign prostatic hyperplasia drug Proscar (finasteride 5 mg) are being updated with an expanded list of adverse sexual effects, the FDA has announced.

The updates:

  • The Propecia label will include libido, ejaculation, and orgasm disorders that persist after treatment ends.

  • The Proscar label will include decreased libido that persists posttreatment.

  • Both labels will note reports of male infertility or poor semen quality that improved after drug discontinuation.

The FDA said: "Despite the fact that clear causal links between finasteride ... and sexual adverse events have NOT been established, the cases suggest a broader range of adverse effects than previously reported."

When these drugs were approved in the 1990s, their labels noted sexual side effects that normalized after treatment ended. In 2011, the FDA updated the labels to warn of persistent, posttreatment erectile dysfunction.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement